AXSM
Price:
$87.25
Market Cap:
$4.19B
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective an...[Read more]
Industry
Biotechnology
IPO Date
2015-11-19
Stock Exchange
NASDAQ
Ticker
AXSM
According to Axsome Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.06B. This represents a change of 17.23% compared to the average of 3.47B of the last 4 quarters.
The mean historical Enterprise Value of Axsome Therapeutics, Inc. over the last ten years is 1.45B. The current 4.06B Enterprise Value has changed 27.94% with respect to the historical average. Over the past ten years (40 quarters), AXSM's Enterprise Value was at its highest in in the June 2024 quarter at 3.73B. The Enterprise Value was at its lowest in in the September 2014 quarter at 0.
Average
1.45B
Median
748.74M
Minimum
62.70M
Maximum
3.42B
Discovering the peaks and valleys of Axsome Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.72%
Maximum Annual Enterprise Value = 3.42B
Minimum Annual Increase = -52.22%
Minimum Annual Enterprise Value = 62.70M
Year | Enterprise Value | Change |
---|---|---|
2023 | 3.42B | 12.74% |
2022 | 3.03B | 118.83% |
2021 | 1.38B | -52.22% |
2020 | 2.90B | -12.63% |
2019 | 3.32B | 4.72% |
2018 | 68.75M | -33.50% |
2017 | 103.39M | 0.98% |
2016 | 102.39M | 63.31% |
2015 | 62.70M | -44.53% |
2014 | 113.02M | 0.11% |
The current Enterprise Value of Axsome Therapeutics, Inc. (AXSM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.61B
5-year avg
2.81B
10-year avg
1.45B
Axsome Therapeutics, Inc.’s Enterprise Value is less than Incyte Corporation (13.32B), less than ImmunoGen, Inc. (8.19B), less than Sarepta Therapeutics, Inc. (12.72B), greater than ACADIA Pharmaceuticals Inc. (2.31B), less than Viking Therapeutics, Inc. (6.99B), less than Madrigal Pharmaceuticals, Inc. (6.99B), greater than Seres Therapeutics, Inc. (278.81M), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than TG Therapeutics, Inc. (3.80B), greater than Terns Pharmaceuticals, Inc. (508.25M), greater than Hepion Pharmaceuticals, Inc. (1.72M), greater than Akero Therapeutics, Inc. (1.95B), less than Reata Pharmaceuticals, Inc. (6.68B), greater than Day One Biopharmaceuticals, Inc. (1.07B), less than Blueprint Medicines Corporation (6.13B), greater than PDS Biotechnology Corporation (85.57M), greater than Amylyx Pharmaceuticals, Inc. (316.21M),
Company | Enterprise Value | Market cap |
---|---|---|
13.32B | $14.59B | |
8.19B | $8.73B | |
12.72B | $11.74B | |
2.31B | $2.43B | |
6.99B | $7.04B | |
6.99B | $7.23B | |
278.81M | $137.42M | |
915.81M | $794.69M | |
3.80B | $3.77B | |
508.25M | $599.50M | |
1.72M | $3.68M | |
1.95B | $2.23B | |
6.68B | $6.57B | |
1.07B | $1.49B | |
6.13B | $5.84B | |
85.57M | $118.93M | |
316.21M | $388.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Axsome Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Axsome Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Axsome Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Axsome Therapeutics, Inc. (AXSM)?
What is the 3-year average Enterprise Value for Axsome Therapeutics, Inc. (AXSM)?
What is the 5-year average Enterprise Value for Axsome Therapeutics, Inc. (AXSM)?
How does the current Enterprise Value for Axsome Therapeutics, Inc. (AXSM) compare to its historical average?